Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ARTS-021 |
Synonyms | |
Therapy Description |
ARTS-021 is a CDK2 inhibitor, which potentially decreases tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2568). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ARTS-021 | ARTS 021|ARTS021|AVZO-021|AVZO021 | CDK2 Inhibitor 31 | ARTS-021 is a CDK2 inhibitor, which potentially decreases tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2568). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Ribociclib ARTS-021 + Letrozole + Ribociclib ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin Abemaciclib + ARTS-021 + Fulvestrant Abemaciclib + ARTS-021 + Letrozole ARTS-021 + Fulvestrant ARTS-021 | Study of AVZO-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |